Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $1023

Benzinga · 10/03 13:49
Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and lowers the price target from $1028 to $1023.